Access cutting-edge myelofibrosis treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access myelofibrosis specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related myelofibrosis treatment provided free
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxol
Sponsor: Kartos Therapeutics, Inc.
Check if you qualify for this myelofibrosis clinical trial in Birmingham, AL
If you're searching for myelofibrosis treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.